Published on in Vol 10, No 9 (2021): September

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/28524, first published .
An Activity Tracker–Guided Physical Activity Program for Patients Undergoing Radiotherapy: Protocol for a Prospective Phase III Trial (OnkoFit I and II Trials)

An Activity Tracker–Guided Physical Activity Program for Patients Undergoing Radiotherapy: Protocol for a Prospective Phase III Trial (OnkoFit I and II Trials)

An Activity Tracker–Guided Physical Activity Program for Patients Undergoing Radiotherapy: Protocol for a Prospective Phase III Trial (OnkoFit I and II Trials)

Franziska Hauth   1, 2 , MD ;   Barbara Gehler   1 , MD ;   Andreas Michael Nieß   3 , MD ;   Katharina Fischer   3 , MA ;   Andreas Toepell   1 , MD ;   Vanessa Heinrich   1 , MD ;   Inka Roesel   4 , MSc ;   Andreas Peter   5 , MD ;   Mirjam Renovanz   6 , MD ;   Andreas Hartkopf   7 , MD ;   Andreas Stengel   8, 9, 10 , MD ;   Daniel Zips   1, 11 , MD ;   Cihan Gani   1, 11 , MD

1 Department of Radiation Oncology, University Hospital Tübingen, Tuebingen, Germany

2 Edwin L Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

3 Department of Sports Medicine, University Medicine Tübingen, Tuebingen, Germany

4 Institute for Clinical Epidemiology and Applied Biostatistics, University Hospital of Tübingen, Tuebingen, Germany

5 Department of Diagnostic Laboratory Medicine, Institute for Clinical Chemistry and Pathobiochemistry, University Hospital of Tübingen, Tuebingen, Germany

6 Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Tuebingen, Germany

7 Department of Obstetrics and Gynecology, University Hospital Tübingen, Tuebingen, Germany

8 Department of Psychosomatic Medicine and Psychotherapy, Medical University Hospital Tübingen, Tuebingen, Germany

9 Comprehensive Cancer Center, Section Psychooncology, University Hospital Tuebingen, Tuebingen, Germany

10 Charité Center for Internal Medicine and Dermatology, Department of Psychosomatic Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany

11 German Cancer Research Center Heidelberg and German Consortium for Translational Cancer Research, Partner Site Tübingen, Tuebingen, Germany

Corresponding Author: